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Background & Aims: Hepatocyte apoptosis is induced by
tumor necrosis factor a (TNF-a) and Fas ligand. Al-
though nuclear factor–kB (NF-kB) activation protects
hepatocytes from TNF-a–mediated apoptosis, the NF-kB
responsive genes that protect hepatocytes are unknown.
Our aim was to study the role of NF-kB activation and
inducible nitric oxide synthases (iNOSs) in TNF-a– and
Fas-mediated apoptosis in hepatocytes. Methods: Pri-
mary cultures of hepatocytes from wild-type and iNOS
knockout mice were treated with TNF-a, the Fas agonis-
tic antibody Jo2, a nitric oxide (NO) donor (S-nitroso-N-
acetylpenicillamine), an NO inhibitor (NG-methyl-L-argi-
nine acetate), and/or adenovirus-expressing NF-kB
inhibitors. Results: The IkB superrepressor and a domi-
nant-negative form of IkB kinase beta (IKKb) inhibited
NF-kB binding activity by TNF-a or Jo2 and sensitized
hepatocytes to TNF-a– and Jo2-mediated apoptosis.
TNF-a and Jo2 induced iNOS messenger RNA and pro-
tein levels through the induction of NF-kB. S-nitroso-N-
acetylpenicillamine inhibited Bid cleavage, the mito-
chondrial permeability transition, cytochrome c release,
and caspase-8 and -3 activity, and reduced TNF-a– and
Fas-mediated death in hepatocytes expressing IkB su-
perrepressor. NG-methyl-L-arginine acetate partially sen-
sitized hepatocytes to TNF-a– and Fas-mediated cell
killing. TNF-a alone or Jo2 alone induced moderate cell
death in hepatocytes from iNOS2/2 mice. Conclusions:
NO protects hepatocytes from TNF-a– and Fas-mediated
apoptosis. Endogenous iNOS, which is activated by
NF-kB via IKKb, provides partial protection from apop-
tosis.
The tumor necrosis factor a receptor (TNFR) familyincludes Fas (also known as APO-1 or CD95), the
receptor for Fas ligand1 (FasL), and 2 TNFRs (TNFR1
and TNFR2). Two death factors, tumor necrosis factor a
(TNF-a) and FasL, bind to their receptors and induce
apoptosis, killing the cells within hours.1,2 TNF both
induces apoptosis and activates the antiapoptotic tran-
scription factor nuclear factor–kB (NF-kB). TNFR1 con-
tains a death domain, TNF-a receptor-associated death
domain protein (TRADD), which interacts with TNF-a
receptor-associated factor 2 (TRAF2). The interaction of
TRADD with TRAF2 and protein kinase receptor inter-
acting protein activates NF-kB–inducing kinase (NIK),
a mitogen-activated protein kinase kinase kinase (MAP-
KKK).3–5 NIK or another unknown MAPKKK activates
the IkB kinase (IKK) complex, which contains IKKa
and IKKb and phosphorylates IkB, which leads to its
degradation and subsequent activation of NF-kB.6–9
Studies with cells from knockout mice suggest that
IKKb, but not IKKa, is required for TNF-a–induced
NF-kB activation.10–12 The activation of the NF-kB by
TNF protects from cell killing.13,14 TNFR-associated
factor 1, TRAF2, and the inhibitor-of-apoptosis (IAP)
proteins c-IAP1 and c-IAP2 were identified as gene
targets of NF-kB transcriptional activity.15 Other anti-
apoptotic genes include IEX-1, A1, and A20.16–19
The Fas/FasL system is of major importance in homeosta-
sis of the organism, in regulation of the immune system,
and in many diseases in which apoptosis plays a role.20
Numerous cells in the liver have been shown to express
Fas/FasL, and the Fas/FasL system plays a major role in the
pathogenesis of many liver diseases, such as viral hepatitis,
Abbreviations used in this paper: FasL, Fas ligand; HDM, hormonally
defined medium; IAP, inhibitor-of-apoptosis; IFN-g, interferon g; IKK,
IkB kinase; IL-1b, interleukin 1b; iNOS, inducible nitric oxide synthase;
L-NMMA, NG-methyl-L-arginine acetate; MAPKKK, mitogen-activated
protein kinase kinase kinase; MPT, mitochondrial permeability transi-
tion; NF-kB, nuclear factor-kB; NIK, NF-kB–inducing kinase; NO, nitric
oxide; PCR, polymerase chain reaction; SDS, sodium dodecyl sulfate;
SNAP, S-nitroso-N-acetylpenicillamine; TMRM, tetramethylrhodamine
methyl ester; TNF-a, tumor necrosis factor a; TNFR, tumor necrosis
factor a receptor; TRADD, tumor necrosis factor a receptor-associated
death domain protein; TRAF2, tumor necrosis factor a receptor-asso-
ciated factor 2; TUNEL, terminal deoxynucleotidyl transferase-medi-
ated deoxyuridine triphosphate nick end labeling.




alcoholic hepatitis, acute liver failure, graft versus host
disease, and hepatocellular carcinoma.21–23 Activating Fas
by FasL or anti-Fas agonistic antibodies such as Jo2 pro-
duces fulminant hepatitis in mice. However, many Fas-
expressing cells including hepatocytes are resistant to Fas-
induced apoptosis in culture, suggesting that cellular factors
exist that inhibit Fas signaling. We have previously shown
that the IkB superrepressor or the proteasome inhibitor
MG-132 sensitized hepatocytes to Fas-mediated apoptosis,
which indicates that NF-kB also has a protective role in
Fas-mediated apoptosis.24 However, how Fas activates
NF-kB or which NF-kB responsive gene has a protective
role in Fas-mediated apoptosis is unclear.
Nitric oxide (NO) acts as either a physiologic regula-
tor or a cytotoxic agent.25,26 NO may cause hepatocyte
injury, primarily through the induction of hepatocyte
apoptosis.27 Alternatively, NO can induce resistance to
TNF-a–induced hepatotoxicity. NO may prevent apop-
tosis in hepatocytes by inhibiting caspase-3–like activa-
tion via a guanosine 39,59-cyclic monophosphate (cGMP)
–dependent mechanism and by direct inhibition of
caspase-3–like activity through protein S-nitrosylation.28
NO may also inhibit TNF-a–induced hepatotoxicity
through the stimulation of heat shock protein 70 expres-
sion.29
The cytokines TNF-a, interleukin 1b (IL-1b), and
interferon g (IFN-g) synergistically activate inducible
nitric oxide synthase (iNOS) expression in the liver.30
However, the association between Fas signaling pathway
and iNOS is unknown. In general, iNOS gene expression
requires the transcription factor NF-kB.30 This study
examines the roles of NF-kB activation, iNOS expres-
sion, and NO synthesis in TNF-a– and Fas-mediated
apoptosis in primary mouse hepatocytes.
Materials and Methods
Primary Hepatocyte Cultures
About 8-week-old C57Bl6 male mice were anesthe-
tized with ketamine/acepromazine malate administered by in-
traperitoneal injection. Hepatocytes were then isolated by a
retrograde, nonrecirculating in situ collagenase perfusion of
livers cannulating through the inferior vena cava by a proce-
dure modified from Moldeus et al.31 Livers were first perfused
in situ with an oxygenated 0.5 mmol/L ethylene glycol-bis(b-
aminoethyl ether)-N,N,N9,N9-tetraacetic acid containing cal-
cium-free salt solution (10 mL/min, 37°C for 5 minutes),
followed by perfusion with solution containing 0.04% colla-
genase type I (Worthington biochemical corporation, Lake-
wood, NJ) for 10 minutes. The liver was then gently minced
on a Petri dish and filtered with polyamide mesh (I 003 Y
NITEX 3-60/45; TETKO Inc., Depew, NY). Hepatocytes
were washed 2 times and centrifuged at 50g for 2 minutes. Cell
viability was consistently .90% as determined by trypan blue
exclusion. Hepatocyte cultures contained less than 1% Kupffer
cells and hepatic stellate cells as determined by fluorescein
isothiocyanate–labeled latex beads (1 mm; Polysciences, War-
rington, PA) and autofluorescence, respectively. 4 3 105 cells
were plated on 6-well plates coated with mouse collagen type
I in Waymouth’s medium containing 10% fetal bovine serum,
0.1 mmol/L insulin, and 0.1 mmol/L dexamethazone. 1.5 3
106 or 4.0 3 106 cells were plated on a 60-mm or 100-mm
dish, respectively. After 1.5 to 2 hours, the culture was washed
with phosphate-buffered saline and changed to hormonally
defined medium (HDM) containing 0.1 mmol/L insulin, 2
mmol/L L-glutamine, 5 mg/mL transferrin, 3 mmol/L sele-
nium, and 10 nmol/L free fatty acids in RPMI basal medium.
Cells were infected with recombinant adenoviruses in HDM
containing 30 plaque forming units/cell for 2 hours at 37°C
and then changed to HDM containing recombinant murine
TNF-a (R&D Systems, Minneapolis, MN), Jo-2 (Pharmingen,
San Diego, CA), or other treatments. In some experiments,
cells were pretreated with NO donor, S-nitroso-N-acetylpeni-
cillamine (SNAP; Molecular Probes, Eugene, OR), or NOS
inhibitor, NG-methyl-L-arginine acetate (L-NMMA; Molecular
Probes) for 2 hours before the exposure of TNF-a or Jo2.
Furthermore, iNOS-null hepatocytes were isolated from iNOS
knockout mice (a kind gift from Dr. O. Smithies and Dr. N.
Maeda).32 All animals received humane care in compliance
with the guidelines of the University of North Carolina.
Adenoviruses
The adenovirus 5 variants Ad5IkB and Ad5LacZ ex-
pressing HA-IkBa (S32A, S36A) and b-galactosidase, respec-
tively, have been described elsewhere.33,34 The adenoviruses,
Ad5IKKadn or Ad5IKKbdn were expressing a catalytic mu-
tant with lysine changed to methionine. Lysates were prepared
from 4 3 105 hepatocytes at 24 hours after adenoviral infec-
tion. The HA-tagged IKKadn or the FLAG-tagged IKKbdn
were detected using mouse anti-HA antibody (Boehringer
Mannheim, Mannheim, Germany) or mouse anti-FLAG anti-
body (Eastman Kodak Company, New Haven, CT), respec-
tively.
Nuclear Extract Preparation and
Electrophoretic Mobility Shift Assay
Four million cells were cultured overnight after adeno-
viral infection. Cells were harvested 30 minutes after TNF-a
or Jo2 treatment. Nuclear protein extracts were prepared from
primary mouse hepatocytes as previously described.33,34 Pro-
tein-DNA binding reactions were performed for 20 minutes
on ice, using 5 mg of nuclear extract and 32P-labeled DNA
probes for the NF-kB consensus binding site.35 Complexes
were separated by electrophoresis on nondenaturing 5% acryl-
amide gels and assayed by autoradiography and PhosphorIm-
ager analysis (Molecular Dynamics, Sunnyvale, CA). For su-
pershift assays, 8 mg of antibody against p65 or p50 subunit of
the NF-kB complex (Santa Cruz Biotechnology, Santa Cruz,
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CA) was added to the reaction mixture, and the incubation
time was extended for an additional 30 minutes.
Measurement of Apoptosis
For quantitation of cell viability (presented as mean 6
SEM), cells were infected and treated as described above. After 17
to 20 hours of TNF-a or Jo-2 treatment, cell viability was
determined by exclusion of trypan blue. Viable cells were counted
in 3 different 2003 power fields, and the percentage of treated
viable cells to untreated viable cells was determined as a percent-
age of control viability. For propidium iodide nuclear staining,
cells were fixed in 3:1 methanol/acetic acid, stained with 10
mg/mL propidium iodide, and viewed with an Olympus fluores-
cence microscope (Olympus America, Melville, NY) using a
rhodamine filter set. Hepatocyte cell death was confirmed as
apoptosis by terminal deoxynucleotidyl transferase-mediated de-
oxyuridine triphosphate nick end labeling (TUNEL; Boehringer
Mannheim). TUNEL staining was performed according to the
manufacturer’s instructions. Positive (apoptotic) cells were
counted in 3 different 2003 power fields. 7-amino-4-triflouro-
methyl coumarin (AFC) release assays for caspase-3 and -8 activ-
ities were performed using the FluorAce kit (Bio-Rad Laborato-
ries, Hercules, CA) according to the manufacturer’s instructions.
Briefly, whole cell lysates were combined with 25 mmol/L z-
DEVD-AFC or IETD-AFC (Enzyme and Systems Products, Liv-
ermore, CA) and were incubated 2 hours at 37°C. Change in
fluorescence (excitation at 370 nm and emission at 490 nm) was
monitored at 1-hour intervals, converted to picomoles of AFC




Total RNA was extracted with RNeasy mini kit (Qia-
gen Inc., Valencia, CA) according to the manufacturer’s in-
structions. First-strand complementary DNA was synthesized
using 1 mg of total RNA, 10 mmol/L deoxynucleoside triphos-
phates (Pharmacia, Piscataway, NJ), and 200 U of Moloney
Murine leukemia virus reverse transcriptase (Gibco, Grand
Island, NY) in a final volume of 25 mL. The reaction was
performed for 60 minutes at 42°C. The synthesized comple-
mentary DNA was amplified using specific sets of primers for
iNOS and b-actin. The iNOS sense primer sequence was
59-TAGAAACAACAGGAACCTACCA-39, and the antisense
primer was 59-ACAGGGGTGATGCTCCATGACA-39. The
primers for b-actin were described before.35 Polymerase chain
reactions (PCRs) were cycled as follows after initial denatur-
ation for 4 minutes at 99.9°C: 40 cycles: 94°C for 30 seconds,
58°C for 30 seconds, and 72°C for 30 seconds; final extension
was carried out at 72°C for 5 minutes. PCR products were
electrophoresed in a 2% agarose gel, stained with ethidium
bromide, and photographed.
Western Blot Analysis
Cell lysates were prepared from 4 3 106 hepatocytes
with or without Ad5IkB infection. Lysates containing 25 mg,
50 mg, or 50 mg of protein were separated by electrophoresis
on 7.5%, 10%, or 10% acrylamide sodium dodecyl sulfate
(SDS) gels for iNOS, caspase-8, or Bid, respectively. The
proteins were transferred into nitocellulose membranes (Schlei-
cher & Schuell, Keene, NH). Equal loading was confirmed by
Ponceau S staining. iNOS was detected using rabbit polyclonal
anti-iNOS antibody (Santa Cruz Biotechnology) and secondary
antirabbit horseradish peroxidase–conjugated antibody (Santa
Cruz Biotechnology). Antirat albumin antibody (Pharmaceu-
ticals, Inc., Aurora, OH) was used for internal control.
Caspase-8 cleavage products, p18, were detected using rabbit
polyclonal anti–caspase-8 antibody (Stressgen, Victoria, BC,
Canada) and secondary antirabbit horseradish peroxidase–con-
jugated antibody (Santa Cruz Biotechnology). Bid was de-
tected using primary polyclonal rabbit Bid antibody (a kind
gift from Dr. X. M. Yin) and secondary antirabbit horseradish
peroxidase–conjugated antibody. Proteins were detected with
enhanced chemLuminesence detection reagents (Amersham
Corp., Arlington Heights, IL).
The preparation of cytosolic S-100 fractions and Western
blot analysis for cytochrome c were performed as described
previously.33 Briefly, S-100 fractions were prepared from 8 3
106 hepatocytes by differential centrifugation in buffer con-
taining 250 mmol/L sucrose. Lysates containing 25 mg of
protein were separated by electrophoresis on 15% acrylamide
SDS gels and transferred into nitocellulose membranes (Schlei-
cher & Schuell). Equal loading was confirmed by Ponceau S
staining. Cytochrome c was detected using primary monoclo-
nal anti–cytochrome c antibody (Pharmingen) and secondary
anti-mouse horseradish peroxidase–conjugated antibody (San-
ta Cruz Biotechnology).
Nitrite 1 Nitrate Assay
4 3 105 hepatocytes were plated onto a 6-well plate.
Culture supernatants were collected 24 hours after treatment
and assayed for nitrite and nitrate (NO22 1 NO32) using
Griess Reagent kit (Molecular Probes) according to the man-
ufacturer’s instructions.
Confocal Microscopy
Cell loading and confocal microscopy were performed
as described previously.33 Briefly, 1.5 3 106 hepatocytes
plated on collagen-coated 40-mm–diameter glass coverslips
were infected with Ad5IkB with or without the pretreatment
with SNAP in HDM supplemented with 50 mmol/L HEPES
(pH 7.0) to stabilize the pH during the confocal measure-
ments. The cells were loaded with 250 nmol/L tetramethyl-
rhodamine methyl ester (TMRM; Molecular Probes) and 1
mmol/L calcein-acetoxymethyl ester (Molecular Probes) in
Krebb Ringer Hepes buffer for 15 minutes at 37°C. The
coverslips were mounted on a Nikon microscope (Nikon,
Melville, NY) in HDM-HEPES containing 100 nmol/L
TMRM, and the temperature was maintained at 37°C. The
first image (time-point 0) was then recorded. Subsequently,
TNF-a or Jo-2 was added to the medium, and images were
collected at given time-points. Calcein and TMRM fluores-
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cence were excited with an argon laser through a double
dichroic reflector at 488 nm and 568 nm, respectively. TMRM
was imaged through a 590-nm–long path emission filter using
a Bio-Rad MRC-600 confocal system (Bio-Rad Laboratories).
Calcein fluorescence was collected through a 515–560-nm
band path emission filter. A numerical aperture 1.4, 603
objective lens was used, and pinholes were set to 4 in both
channels. Laser attenuation and power were set at 0.3% and
low, respectively.
Results
IkB Superrepressor and dnIKKb Inhibit the
Induction of NFkB Binding Activity by TNF-a
or Anti-Fas Antibody
To determine the roles of NF-kB and IKKs in
TNF-a– and Fas-mediated apoptosis in primary mouse
hepatocytes, adenoviruses expressing an HA-tagged kinase-
inactive mutant of IKKa (dnIKKa) and a FLAG-tagged
kinase-inactive mutant of IKKb were generated. NF-kB
binding activity was assessed by mobility shift assays using
an NF-kB binding site as a probe. Nuclear extracts were
prepared from primary mouse hepatocytes 30 minutes after
treatment of TNF-a or anti-Fas agonistic antibody, Jo2,
with or without adenoviral infection. TNF-a treatment for
30 minutes induced an increase in NF-kB DNA binding
activity (Figure 1A), as described before.24 Expression of
dnIKKb or the IkB superrepressor completely inhibited
TNF-a–induced NF-kB binding activity. The dnIKKa
suppressed TNF-a–induced NF-kB binding activity to a
lesser extent than dnIKKb. Furthermore, Jo2 treatment
also induced NF-kB binding activity (Figure 1B). Jo2-
induced NF-kB binding activity was completely inhibited
in IkB superrepressor- and dnIKKb-expressing hepato-
cytes. The NF-kB complex activated by TNF-a or Jo2
treatment was composed of p50-p65 dimers, as determined
by supershifts (Figure 1A and B). Control adenovirus ex-
pressing b-galactosidase had no effect on TNF-a– or Jo2-
induced NF-kB binding activity (data not shown). These
results show that TNF-a and Jo2 activate NF-kB through
IKKs, especially IKKb, in mouse hepatocytes.
The dnIKKb Expression Sensitizes Mouse
Hepatocytes to TNF-a– or Fas-mediated
Apoptosis
To investigate the roles of IKKs in TNF-a– and
Fas-mediated hepatocyte apoptosis, we infected mouse
hepatocytes with dnIKKa adenovirus or dnIKKb ade-
novirus and treated cells with TNF-a or anti-Fas anti-
body. The expression of the IKKs was confirmed by
Western blotting using HA or FLAG tag (Figure 2C,
upper panel ). TNF-a or Jo2 treatment killed the hepato-
cytes expressing dnIKKb, but not dnIKKa (Figure 2A
and C ). The hepatocytes expressing dnIKKb treated
with TNF-a or Jo2 displayed nuclear condensation and
fragmentation by propidium iodide staining, character-
istic of apoptosis (Figure 2B, right panel ), whereas cells
expressing dnIKKa displayed almost normal nuclear
morphology after TNF-a or Jo2 treatment (Figure 2B,
left panel ). To confirm death by apoptosis, a TUNEL
assay was performed. Although TUNEL-positive cells
were minimal after TNF-a or Jo2 treatment in hepato-
cytes expressing dnIKKa (2.0 6 1.0, 11.7 6 1.5,
mean 6 SEM cells/3200, respectively), positive hepato-
cytes were observed after TNF-a or Jo2 treatment in
dnIKKb adenovirus–infected hepatocytes (57.7 6 5.2
and 50.0 6 5.3, respectively). These results show that
NF-kB activation, mediated by IKKb, but not IKKa,
protects primary mouse hepatocytes from TNF-a– or
Fas-mediated apoptosis.
TNF-a or anti-Fas Antibody Induces iNOS
Expression, Which Is Blocked by IkB
Superrepressor
A critical question is which NF-kB–responsive gene
protects hepatocytes from TNF-a– or Fas-mediated apopto-
Figure 1. The IkB superrepressor or dominant-negative form of IKKb
blocks TNF-a– and Fas-mediated NF-kB binding activity. NF-kB DNA
binding activity was assessed by an electrophoretic mobility shift
assay using an NF-kB binding site as the probe with nuclear extracts
prepared after a 30-minute incubation with (A) TNF-a or (B) Jo2 with or
without adenovirus infection with Ad5IkB, Ad5IKKadn, Ad5IKKbdn (30
multiplicity of infection [MOI]) for 2 hours. For supershift assays, 8 mg
of antibody against p65 or p50 subunit of the NF-kB complex was
added to the reaction mixture, and the incubation time was extended
for an additional 30 minutes.
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sis. Among antiapoptotic NF-kB responsive genes, we fo-
cused on iNOS, which synthesizes NO. iNOS is an NF-
kB–responsive gene induced by TNF.30 NO, the product of
iNOS, is a protective factor against TNF toxicity in several
cell types.28,36 To determine if TNF-a and Jo2 induce
iNOS, we performed reverse-transcription PCR and West-
ern blot analysis for iNOS. TNF-a induced iNOS messen-
ger RNA (mRNA) by 1 hour after treatment with higher
iNOS mRNA levels at 2 and 4 hours (Figure 3A). Jo2
induced iNOS mRNA after 4 hours of treatment. These
results indicate iNOS mRNA expression precedes caspase-3
activation in TNF-a– and Fas-mediated apoptosis.24 The
iNOS mRNA expression was blocked in hepatocytes ex-
pressing the IkB superrepressor. Consistent with the
mRNA results, iNOS protein was induced by TNF-a or
Jo2, which was blocked by Ad5IkB infection (Figure 3B).
As expected, TNF-a or Jo2 does not induce iNOS in iNOS
knockout hepatocytes (Figure 3B). Treatment with TNF-a
or Jo2 produced NO, as documented by the accumulation
of nitrite and nitrate in the media (Figure 4A). These results
indicate that TNF-a or anti-Fas agonistic antibody induces
iNOS expression, which is blocked by IkB superrepressor,
and that iNOS is an NF-kB–responsive gene in hepato-
cytes.
NO Protects Mouse Hepatocytes From
TNF-a– or Fas-mediated Apoptosis
To explore the effect of iNOS and NO in
TNF-a– or Fas-mediated apoptosis, we used the NO
donor SNAP in the mouse hepatocytes. SNAP pro-
duced NO, as documented by the accumulation of
nitrite and nitrate in the media (Figure 4A). Because
NO enhances activation of NF-kB in some other cell
types,37 we determined whether NO activates NF-kB.
However, SNAP reduced NF-kB binding activity by
TNF-a or Jo2 in hepatocytes, whereas the IkB super-
repressor completely blocks NF-kB binding activity
by TNF-a or Jo2 (Figure 4B). Hepatocytes expressing
IkB superrepressor were treated with TNF-a or Jo2
with or without pretreatment with SNAP. Without
Figure 3. TNF-a or anti-Fas antibody induces iNOS expression,
which is blocked by the IkB superrepressor. (A) Total RNA was
extracted at the indicated times after treatment with TNF-a (30
ng/mL) or Jo2 (0.5 mg/mL). Some cultures were pretreated by
Ad5IkB infection. iNOS mRNAs were measured using reverse-tran-
scription PCR analysis as described in Materials and Methods. (B)
Lysates were prepared from 4 3 106 hepatocytes at 24 hours after
TNF-a or Jo2 treatment. Lysates containing 25 mg protein were
separated by electrophoresis on 7.5% acrylamide SDS gel. iNOS
(upper panel) was detected by the Western blotting. Albumin was
also detected for the internal control.
Figure 2. The dominant-negative form of IKKb, but not IKKa, sen-
sitizes mouse hepatocytes to TNF-a– and Fas-mediated apoptosis.
(A) Primary mouse hepatocytes were treated with TNF-a (30 ng/mL,
upper panel) or Jo2 (0.5 mg/mL, lower panel) after AdIKKadn or
AdIKKbdn infection (30 MOI). Phase contrast images of mouse
hepatocytes were obtained at 21 hours after the treatment (origi-
nal magnification 2003). (B) Propidium iodide–stained images of
TNF-a–treated (upper panel) and Jo2-treated cells (lower panel) at
17 hours after the treatment (original magnification 4003). (C) The
HA-tagged IKKadn or the FLAG-tagged IKKbdn was detected by
Western blotting in whole extracts after adenovirus infection using
anti-HA antibody or anti-FLAG antibody, respectively (upper panel).
Cell viability was assessed after 20 hours by a trypan blue exclu-
sion test. Data are shown as average percent viability 6 SEM of 2
to 4 different experiments (lower panel).
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SNAP, the expression of IkB superrepressor sensitizes
hepatocytes to TNF-a– and Fas-mediated cell killing,
as described before24,33 (Figure 4C ). In contrast, SNAP
significantly blocked TNF-a– and Fas-mediated cell
killing. However, more than 500 mmol/L of SNAP
was toxic to the hepatocytes. NO may also inhibit
TNF-a–induced hepatotoxicity through the stimula-
tion of heat shock protein 70 expression.29 However,
250 mmol/L of SNAP was not sufficient for induction
of heat shock protein 70, shown by Western blot
analysis (Kim et al.29 and data not shown). These
results showed that moderate exogenous NO levels
protect hepatocytes from TNF-a– and Fas-mediated
cell killing and that this protective effect is not a
result of NF-kB activation by NO or heat shock
protein 70 induction.
NO Blocks TNF-a– and Fas-mediated
Activation of Caspase-8, Bid,
and Caspase-3
To determine the mechanism by which NO
blocks TNF-a– and Fas-mediated apoptosis, we investi-
gated the expression of Bid and activation of caspase-8
and caspase-3 with or without the pretreatment with
SNAP. The cleavage product of caspase-8, p18, was
detected in cell lysates from hepatocytes 6 hours after
TNF-a treatment and 1.5 hours after Jo2 treatment.
However, SNAP inhibited activation of caspase-8 (Fig-
Figure 4. NO donor, SNAP, protects mouse hepatocytes from TNF-a–
and Fas-mediated apoptosis. (A) Cultured mouse hepatocytes were
treated with SNAP, TNF-a, or Jo2. Culture media were collected 24
hours after treatment and NO22 1 NO32 release were measured by
the Griess reaction. Values are expressed as the mean 6 SEM of 2
different experiments. (B) NF-kB DNA binding activity was assessed by
an electrophoretic mobility shift assay using an NF-kB binding site as
the probe with nuclear extracts prepared after a 30-minute incubation
with TNF-a or Jo2 with or without the pretreatment of SNAP for 2
hours. (C) Cell viability was assessed at 17 hours after TNF-a or Jo2
treatment with or without the pretreatment of SNAP in hepatocytes
expressing IkB superrepressor by a trypan blue exclusion test. Data
are shown as average percent viability 6 SEM of 2 to 4 different
experiments.
Figure 5. NO blocks TNF-a– and Fas-induced activation of caspase-8,
Bid, and caspase-3. Hepatocytes were either treated with TNF-a or
Jo2 after Ad5IkB infection. Some cultures were pretreated by SNAP.
Cell lysates were prepared (4 3 106 cells) at the times indicated.
Caspase-8 cleavage product, p18 (A), and p22 Bid (B) were detected
by Western blotting as described under Materials and Methods. (C)
Ad5IkB-infected hepatocytes were treated with TNF-a (30 ng/mL) or
Jo2 (0.5 mg/mL), and then lysed and assayed for caspase-3 activity at
1-hour intervals. Data are shown as average fold-increases of basal
levels without treatment 6 SEM of 2 different experiments performed
in duplicate.
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ure 5A ). Furthermore, catalytic assays using IETD-AFC
substrate showed SNAP reduced caspase-8 activivation
by TNF-a and Jo2 in hepatocytes expressing IkB super-
repressor (data not shown). Cleavage of Bid mediates
mitochondrial dysfunction and cytochrome c in some
apoptotic pathways;38,39 and Bid is essential for the ap-
optosis of selected cells, because Bid-deficient mice are
resistant to Fas-induced hepatocellular apoptosis.40 Bid
was cleaved after TNF-a or Jo2 in hepatocytes expressing
the IkB superrepressor (Figure 5B ). However, SNAP
blocked the cleavage of Bid by TNF-a or Jo2 in hepa-
tocytes expressing IkB superrepressor. The activity of the
effector caspase, caspase-3, was reduced by the pretreat-
ment with SNAP in TNF-a– and Jo2-treated cells (Fig-
ure 5C).
NO Blocks the Mitochondrial Permeability
Transition and Cytochrome c Release
Induced by TNF-a or anti-Fas Antibody in
Hepatocytes Expressing the IkB
Superrepressor
The mitochondrial permeability transition (MPT)
is an essential component in the signaling pathways in
TNF-a–mediated cytotoxicity in the L929 line of mouse
fibroblast41 and in TNF-a–induced apoptosis in rat and
mouse hepatocytes.24,33 To determine the effect of NO on
the MPT, we monitored the MPT and mitochondrial
depolarization using calcein and TMRM, respectively.
TNF-a induced the MPT and mitochondrial depolariza-
tion from 8 to 10 hours after treatment in Ad5IkB-
infected hepatocytes (data not shown), as described be-
fore in rat and mouse hepatocytes.24,33 However, after
pretreatment with SNAP, even 10 hours after treatment
with TNF-a, each TMRM-labeled mitochondrion corre-
sponded to a dark void in the calcein image, showing
that the mitochondria were polarized and impermeable
to low-molecular-weight solutes (Figure 6A ). This result
indicates that SNAP blocks the MPT and mitochondrial
depolarization. At 3.5 hours after treatment of Jo2, some
mitochondria filled with calcein fluorescence (Figure 7,
lower right panel ), showing permeabilization of the inner
mitochondrial membrane, corresponding to onset of the
MPT. Simultaneously, these mitochondria lost TMRM
fluorescence, indicating depolarization (Figure 7, upper
right panel ). In contrast, the dark void in the calcein
image was intact at 3.5 hours after Jo2 treatment in
Ad5IkB-infected hepatocytes pretreated with SNAP,
showing that pretreatment with SNAP clearly main-
tained mitochondrial function (Figure 8A ).
Western blot analysis for cytochrome c release using in
the cytoplasm showed the pretreatment of 250 mmol/L of
SNAP inhibited cytochrome c release by TNF-a (Figure
6B) or Jo2 (Figure 8B). Thus, NO inhibits the MPT and
cytochrome c release.
NOS Inhibitor Sensitizes Mouse
Hepatocytes to TNF-a– or Fas-mediated
Apoptosis
Hepatocytes were pretreated with an iNOS inhib-
itor at a variety of concentrations before TNF-a or Jo2
treatment. The administration of the iNOS inhibitor,
L-NMMA, sensitized hepatocytes to TNF-a– and Fas-
mediated cell killing without the IkB superrepressor
(Figure 9). L-NMMA increased cell killing by 30%–
70%. These results indicate that iNOS is one of the
genes mediating resistance to TNF-a– and Fas-mediated
cell killing.
Figure 6. NO donor blocks the MPT and cytochrome c release in-
duced by TNF-a in hepatocytes expressing IkB superrepressor. (A)
Primary mouse hepatocytes were incubated with TNF-a (30 ng/mL)
after Ad5IkB infection (30 MOI), pretreated with SNAP (500 mmol/L),
and then loaded with calcein (lower panel) to monitor the MPT and
TMRM (upper panel) to monitor mitochondrial depolarization. Calcein
and TMRM fluorescence were monitored simultaneously over time by
confocal microscopy. The images were obtained before (left panel)
and 10 hours after Jo2 treatment (right panel). (B) The preparation of
cytosolic S100-fractions and Western blot analysis for cytochrome c
were performed as described previously.33 SNAP blocked cytochrome
c release from mitochondria by TNF-a.
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TNF-a or anti-Fas Antibody Alone Induces
Moderate Cell Killing in iNOS-null
Hepatocytes
Finally, to investigate the requirement for iNOS
in the protection from TNF-a– and Fas-mediated apop-
tosis, we used iNOS knockout mice. As described above,
no iNOS protein was expressed in these hepatocytes
(Figure 3B). TNF-a or Jo2 alone did not kill hepatocytes
from wild-type mice (Figure 10A ). However, in iNOS
knockout hepatocytes, TNF-a or Jo2 induced moderate
cell killing, of approximately 50% of the cells, without
the IkB superrepressor. NF-kB binding activity by
TNF-a or Jo2 was similar in wild-type and iNOS knock-
out mice (Figure 10B). These results indicate iNOS
provides partial protection from TNF-a– and Fas-medi-
ated apoptosis.
Discussion
This study was undertaken to determine the pro-
tective roles of NF-kB activation and subsequent induc-
tion of iNOS in TNF-a– and Fas-mediated apoptosis.
We showed that (1) NF-kB activation mediated by
IKKb has a protective role in TNF-a– and Fas-mediated
apoptosis; (2) TNF-a or anti-Fas agonistic antibody in-
duces iNOS, which requires NF-kB activation; (3) NO
protects hepatocytes from TNF-a– and Fas-mediated
apoptosis via inhibition of Bid, the MPT, cytochrome c
release, and caspase-3 and -8 activation; and (4) iNOS
provides partial protection from TNF-a– and Fas-medi-
ated apoptosis.
The IKK complex is composed of at least 3 subunits,
IKKa, IKKb, and IKKg (NEMO).42 IKKa and IKKb
are highly similar catalytic subunits, and both are capa-
ble of IkB phosphorylation in vitro, whereas IKKg is a
regulatory subunit.7,9,43,44 Previous biochemical and ge-
netic analyses indicated that disruption of the IKKa
Figure 8. NO donor blocks the MPT and cytochrome c relase induced
by Jo2 in hepatocytes expressing IkB superrepressor. (A) Primary
mouse hepatocytes were incubated with Jo2 (0.5 mg/mL) after
Ad5IkB infection (30 MOI), pretreated with SNAP (500 mmol/L), and
then loaded with calcein (lower panel) to monitor the MPT and TMRM
(upper panel) to monitor mitochondrial depolarization. Calcein and
TMRM fluorescence were monitored simultaneously over time by con-
focal microscopy. The images were obtained before (left panel) and
3.5 hours after Jo2 treatment (right panel). (B) The preparation of
cytosolic S100-fractions and Western blot analysis for cytochrome c
were performed as described previously.33 SNAP blocked cytochrome
c release from mitochondria by Jo2.
Figure 7. Jo2 induces the MPT in hepatocytes expressing IkB super-
repressor. Primary mouse hepatocytes were treated with Jo2 (0.5
mg/mL) after Ad5IkB infection (30 MOI) and then loaded with (B)
calcein (lower panel) to monitor the MPT and (A) TMRM (upper panel)
to monitor mitochondrial depolarization. Calcein and TMRM fluores-
cence were monitored simultaneously over time by confocal micros-
copy. The images were obtained before (left panel) and 3.5 hours
after Jo2 treatment (right panel).
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gene does not abolish activation of IKK by proinflam-
matory stimuli and resulted in only a small decrease in
NF-kB activation.12 IKKb-deficient mice die at mid-
gestation from uncontrolled liver apoptosis, and IKKb
knockout fibroblasts have decreased cytokine-induced
IKK activity.10,11 Consistent with these reports using
embryonic fibroblasts, our study showed that TNF-a and
Jo2 activate NF-kB through IKKs, especially IKKb, in
adult mouse hepatocytes (Figure 1). Furthermore,
NF-kB activation, mediated by IKKb, but not IKKa,
protects primary mouse hepatocytes from TNF-a– or
Fas-mediated apoptosis.
A previous study showed that Fas stimulates the DNA
binding activity of NF-kB in a variety of cells, irrespective
of their sensitivity or resistance to Fas-mediated cytotoxic-
ity.45 Expression of a mutant kinase-deficient NIK blocks
NF-kB induction by TNF-a and Fas.4 We have previously
shown that an adenoviral-mediated expression of the trun-
cated NIK blocks NF-kB binding activity induced by
TNF-a or Jo2 and sensitizes hepatocytes to TNF-a– and
Fas-mediated apoptosis in primary mouse hepatocytes.24 In
this study, we showed that IKKb is critical in NF-kB
activation by TNF-a or Jo2 in primary mouse hepatocytes.
However, the mechanism by which Jo2 activates NIK and
IKKb remains elusive. Recent reports showed both Akt and
NIK are necessary for TNF activation of NF-kB in 293
cells. Akt mediates IKKa phosphorylation at threonine
23.46 In primary mouse hepatocytes, Jo2 phosphorylated
Akt, and constitutively active Akt induced activation of
NF-kB (Hatano E and Brenner DA, unpublished data).
Therefore, we suggest that Jo2 might have alternative path-
ways to activate NF-kB, whereas TNFR1 interacts with
TRADD, TRAF2, and protein kinase receptor interacting
protein and activates NIK (or another MAPKKK) and
IKKb.3–5
The molecular regulation of iNOS expression is com-
plex and occurs at multiple levels.30 Cytokine mixtures,
such as TNF-a, IL-1b, and IFN-g, synergistically acti-
vate iNOS expression in the liver.47 In previous reports,
single cytokines did not induce iNOS, and rat hepato-
cytes were stimulated with a cytokine mixture including
IL-1b and IFNg. However, the treatment of TNF-a
alone was sufficient to induce iNOS in primary mouse
hepatocytes in this study (Figure 3). Interestingly, anti-
Fas antibody Jo2 also induced iNOS mRNA and protein
levels, which were blocked by expression of the IkB
superrepressor. This indicates that NF-kB activation is
necessary for iNOS induction. Several previous reports
Figure 9. NOS inhibitor, L-NMMA, sensitizes mouse hepatocytes to
TNF-a– and Fas-mediated apoptosis. Cell viability was assessed at 17
hours after TNF-a or Jo2 treatment with or without NOS inhibitor,
L-NMMA, by a trypan blue exclusion test. Data are shown as average
percent viability 6 SEM of 2–4 different experiments.
Figure 10. TNF-a or Jo2 induces moderate cell death in iNOS2/2
hepatocytes. (A) Cell viability was assessed at 17 hours after TNF-a or
Jo2 treatment in hepatocytes from wild-type (wt) mice or iNOS knock-
out mice by a trypan blue exclusion test. Data are shown as average
percent viability 6 SEM of 2–4 different experiments. (B) NF-kB DNA
binding activity was assessed by an electrophoretic mobility shift
assay using an NF-kB binding site as the probe with nuclear extracts
from hepatocytes from wt mice or iNOS knock-out mice after 30
minutes incubation with TNF-a.
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have also shown NF-kB activation is required for induc-
tion of iNOS in other-cell types.48,49 However, transcrip-
tion of iNOS in rat mesangial cells requires additional
signals besides activation of NF-kB.50 In skin-derived
dendritic cells, JAK2 and p38MAPK are involved in
iNOS expression.51 Because TNF-a and Jo2 activate
p38MAPK in mouse hepatocytes (Hatano E and Brenner
DA, unpublished data), activation of NF-kB might be
necessary but not sufficient for transcription of iNOS.
NO is known to have both proapoptotic and antiapop-
totic effects. iNOS induction might have proapoptotic
effects on inhibition of mitochondrial function or the
generation of highly toxic peroxynitrite.52 Meanwhile,
NO may prevent apoptosis in induction of cGMP-de-
pendent kinases and by S-nitrosylation of the catalytic
activity of caspases.26,28,36 Low basal NOS activity inhib-
its spontaneous apoptosis in B lymphocytes.53 Further-
more, the basal NOS activity in human leukocytes in-
hibits Fas-induced apoptosis via a cGMP-independent
mechanism.54 NO also mediates protection from TNF-
a–mediated apoptosis in endothelial cells and hepato-
cytes, possibly by heat shock protein induction or caspase
inhibition.29,55 Hsp 70 was not induced in our study,
which generated NO by endogenous iNOS or by low
concentrations of SNAP. Cellular susceptibility towards
apoptotic signaling pathways can effectively be regulated
by low level NO pretreatment. In our study, higher
concentration of NO produced by the pretreatment of
more than 500 mmol/L of SNAP was cytotoxic to pri-
mary mouse hepatocytes, whereas lower concentrations of
SNAP were protective from TNF-a– and Fas-mediated
apoptosis (Figure 4C ). It has been reported that NO
down-regulates iNOS gene transcription, and that the
effect is mediated in part by inhibiting NF-kB activity.56
These results indicate a negative feedback mechanism,
whereby the product NO down-regulates iNOS gene
expression. Consistent with this report, we showed that
SNAP reduced NF-kB binding activity (Figure 4B).
Although NF-kB is down-regulated by SNAP, SNAP
itself protected mouse hepatocytes from TNF-a– and
Fas-mediated apoptosis. Furthermore, the study using
iNOS knockout mice showed that TNF-a or Jo2 induces
moderate cell killing in iNOS knockout hepatocytes
without sensitization by IkB superrepressor (Figure 10).
These results indicate NO produced by iNOS is a
critical antiapoptotic regulator. Interestingly, iNOS
knockout mice have decreased hepatocyte proliferation
after partial hepatectomy, providing additional evidence
for the key role of iNOS in TNF-a–stimulated hepato-
cytes.57 However, TNF-a– or Fas-induced cell death in
iNOS null hepatocytes was moderate, approximately
50%, compared with cell death by TNF-a or Jo2 in
wild-type hepatocytes expressing the IkB superrepressor.
Therefore, additional NF-kB responsive genes must be
required for the complete protection from TNF-a– and
Fas-mediated apoptosis. Recently, it has been shown that
prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcrip-
tional target of NF-kB.18,58 Furthermore, NF-kB di-
rectly activates the expression of Bcl-xL.59 Furthermore,
Akt regulates T lymphocyte survival, NF-kB activation,
and Bcl-xL levels.60 The roles of these NF-kB responsive
antiapoptotic genes in TNF-a– and Fas-mediated apop-
tosis in hepatocytes require further study.
NO inhibits the proteolytic cleavage of caspase-3
(CPP32) into its active subunits, thereby suppressing
caspase-3 activity.55 In addition, NO potently inhibits
apoptosis induction by overexpresssion of Fas associated
death domain protein or its immediate downstream tar-
get caspase-8. These results suggest that NO modulates
the proteolytic cascade upstream of caspase-3. Indeed,
NO specifically S-nitrosylates caspase-8 and caspase-1
and thereby may prevent activation of the proteolytic
cascade.61 A recent report showed that NO inhibits
TRADD recruitment and caspase-8 activity via a cGMP-
dependent mechanism in U937 cells and that this effect
was overcome by incubation of the cells with exogenous
ceramide.62 Bid is a proapoptotic BH3-only member of
the Bcl-2 family, which is proteolytically activated and
translocated to the mitochondria to induce cytochrome c
release.38–40 Bid is a specific substrate of caspase-8 in the
Fas apoptotic signaling pathway.38 We have previously
shown that the MPT is a downstream target of caspase-
8.24,33 Furthermore, the MPT is obligatory for TNF-a–
induced apoptosis. In Fas-mediated apoptosis, the MPT
accelerates the apoptogenic events, but is not obligatory
for them.24 In the present study, TNF-a and Jo2 caused
caspase-8 activation, Bid cleavage, the MPT, cytochrome
c release, and caspase-3 activation, which were all blocked
by pretreatment with SNAP in primary mouse hepato-
cytes (Figures 5–8). These results indicate that NO
blocks targets upstream of the mitochondria, such as
caspase-8 activation. TNF-a– and Fas-mediated apopto-
sis has been shown to play a major role in the pathogen-
esis of numerous liver diseases.21,23,63 Therefore, NF-kB
and/or the NF-kB responsive gene iNOS may be thera-
peutic targets for many kinds of liver diseases.
In conclusion, our study shows that both TNF-a and Fas
induce iNOS through IKKb and subsequent NF-kB acti-
vation to inhibit apoptotic events. However, iNOS induc-
tion is not sufficient for complete protection, indicating that
additional NF-kB responsive genes have antiapoptotic func-
tions in hepatocytes.
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